PHARMACY

Mylan announces Lipitor, Caduet patent settlements

BY Alaric DeArment

PITTSBURGH — Generic drug maker Mylan has entered settlements with Pfizer concerning two drugs for treating cholesterol.

Mylan announced Tuesday that it had settled patent litigation suits with Pfizer concerning Lipitor (atorvastatin calcium) and Caduet (atorvastatin calcium and amlodipine besylate).

Under the Caduet agreement, the lawsuit will be dismissed, and Mylan can launch its generic version on Nov. 30. Terms of the Lipitor agreement remain confidential.

Caduet had sales of $389 million during the 12-month period ended in September 2010, according to IMS Health, while Lipitor had sales of $7.27 during the same period.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Head of Lilly’s oncology biz resigns

BY Allison Cerra

INDIANAPOLIS — John Johnson is bidding Eli Lilly adieu.

Johnson, who served as SVP and president of the drug maker’s oncology business — whose portfolio includes Alimta (pemetrexed) and Gemzar (gemcitabine hydrochloride) — resigned, effective Jan. 28. Johnson is taking on the chief executive role at specialty biopharmaceutical company Savient, effective Jan. 31. Savient is best known for its chronic gout treatment Krystexxa (pegloticase), which received regulatory approval in September 2010.

Johnson said that his role at Savient will focus on successfully launching Krystexxa on a global scale.

"I am thrilled to be joining Savient at this exciting time," Johnson said. "Krystexxa is a product that has potential to make a significant difference in the lives of patients around the world. I look forward to working with the dedicated and talented Savient employees to bring relief to those adult patients suffering from chronic gout refractory to conventional therapy."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Matrix Labs’ generic Protonix DR receives FDA approval

BY Alaric DeArment

PITTSBURGH — The Food and Drug Administration has approved a treatment for gastroesphageal reflux disease made by a subsidiary of Mylan, the generic drug maker said Monday.

The FDA approved Matrix Labs’ pantoprazole sodium delayed-release tablets in the 20-mg and 40-mg strengths.

The drug is a version of Protonix DR, made by Wyeth, now part of Pfizer. Various versions of the drug had sales of around $1.7 billion during the 12-month period ended in September, according to IMS Health. The FDA also approved a version made by Dr. Reddy’s Labs on Friday.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES